India IVF secures $1.25 Million Investment from Tomorrow Capital

IMT News Desk
IMT News Desk
· 2 min read

The new funding will enable the company to bridge critical gaps in fertility care access

India IVF, a pioneering fertility provider founded by Dr Richika Sahay and Dr Somendra Shukla in 2014, has secured $1.25 million in pre-Series A funding from Tomorrow Capital, a $100 million venture capital fund dedicated to supporting early-stage, transformative consumer healthcare businesses.

The investment represents India IVF’s first external funding since its inception, following a decade of profitable operations across its five North Indian centers, which include clinics in Delhi NCR and Srinagar.

The new funding from Tomorrow Capital will drive India IVF’s expansion across North India, enabling the company to bridge critical gaps in fertility care access. With the goal of making advanced fertility solutions accessible to underserved communities, India IVF has established India’s first tech-enabled fertility platform, offering comprehensive, 360-degree fertility care through advanced technology and a dedicated team of experts. Tomorrow Capital’s investment follows its recent support of VitusCare and IndiShreshtha, further reinforcing its commitment to specialized healthcare ventures.

Rahul Saha, Senior Principal, Tomorrow Capital said, “India IVF has shown remarkable growth and a deep understanding of the unique fertility challenges faced by many Indian couples. With a tech-enabled, patient-focused approach, they deliver high-quality personalizsed care, addressing the often-emotional and stigma-attached journey of fertility treatment. Tomorrow Capital backs ventures that drive meaningful impact, and with India IVF, we’re proud to enable access to essential fertility care across underserved regions in India. We believe their innovative approach will set new standards in India’s fertility sector, and we are excited to support their mission to make fertility care more accessible across the country.”

Dr Somendra Shukla, Co-Founder and CEO, India IVF, commented, “This partnership will empower us to expand our network and bring advanced fertility solutions to more communities. We look forward to making a positive impact on more families and growing India IVF into a trusted national brand.”

Dr Richika Sahay, Co-Founder and Medical Director, added, “Approximately 30 million couples in India suffer from infertility, yet only 10 per cent receive proper treatment due to limited access to fertility care. Our mission is to leverage technology and innovation to deliver quality, affordable, and empathetic fertility care to everyone. With Tomorrow Capital’s support, we are well-positioned to expand access to fertility care across North India.”

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk